Combination therapies augment the anti-tumor activity of agonist CD27 mAb in human CD27 transgenic mouse models
Main Authors: | He, Li-Zhen, Thomas, Lawrence J, Testa, James, Weidlick, Jeffrey, Sisson, Crystal, Hammond, Russell, Vitale, Laura, Marsh, Henry, Keler, Tibor |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990982/ |
Similar Items
-
The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent
by: He, Li-Zhen, et al.
Published: (2015) -
Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
by: Thomas, Lawrence J, et al.
Published: (2014) -
Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine
by: He, Li-Zhen, et al.
Published: (2015) -
Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
by: Ramakrishna, Venky, et al.
Published: (2015) -
Immune correlates of Varlilumab treated cancer patients are consistent with CD27 costimulatory activity
by: Bullock, Timothy, et al.
Published: (2014)